Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) on Wednesday announced an agreement to acquire Clario Holdings Inc, a provider of endpoint data solutions for clinical trials.

Under the agreement, Thermo Fisher Scientific will pay USD8.875bn in cash plus up to USD525m in contingent payments based on performance.

Clario's technology integrates clinical endpoint data from devices, sites, and patients, enabling digital collection and analysis across all phases of drug development. Its platform has supported approximately 70% of US Food and Drug Administration (FDA) drug approvals over the past decade.

Thermo Fisher said that the acquisition will enhance its digital and data analytics capabilities, strengthen its artificial intelligence initiatives, and provide deeper clinical insights for pharmaceutical and biotechnology clients. Clario's offerings -- including electronic clinical outcome assessments, medical imaging, and wearable data capture -- are expected to accelerate innovation and improve decision-making in clinical research.

Financially, the deal is expected to be immediately accretive to adjusted earnings per share, adding USD0.45 in the first year post-close and achieving a double-digit internal rate of return. Thermo Fisher anticipates approximately USD175m in adjusted operating income synergies within five years.

Following the close, Clario will operate within Thermo Fisher's Laboratory Products and Biopharma Services segment.

Subject to regulatory approval, Thermo Fisher Scientific expects to complete the acquisition by mid-2026.